Literature DB >> 2522792

Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.

G J Peters1, B J Braakhuis, E A de Bruijn, E J Laurensse, M van Walsum, H M Pinedo.   

Abstract

Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR). 5-FU sensitivity at the maximum tolerated dose (MTD) showed the following pattern; HNX-DU less than HNX-KE = HNX-E = HNX-G less than Colon 26 much less than Colon 38. The sensitivity pattern to 5'd-FUR was: HNX-DU less than HNX-G less than HNX-E less than HNX-KE less than Colon 38 less than Colon 26. For HNX-KE, HNX-E and Colon 26 an increase in therapeutic efficacy was observed with 5'd-FUR as compared to 5-FU; Colon 38 was as sensitive to 5'd-FUR as to 5-FU. Plasma pharmacokinetics of 5'd-FUR and 5-FU were comparable in normal and nude mice. Metabolism of 5-FU and 5'd-FUR was studied in the tumours. Conversion of 5'd-FUR to 5-FU was highest in Colon 26 and 15-20 times lower in HNX-DU, HNX-KE and Colon 38. The Km for 5'd-FUR in all tumours was 1-2 mM. Further anabolism of 5-FU to fluorouridine (FUR) was 5-10 times higher than that of 5-FU to FUR in HNX tumours and 3 times in the colon tumours. 5-FU conversion to FUMP via FUR had the following pattern: Colon 26 much greater than HNX-DU greater than HNX-G greater than HNX-E greater than HNX-KE much greater than Colon 38; of 5-FU to FdUMP via FUdR: Colon 26 greater than HNX-DU = HNX-KE greater than HNX-E greater than HNX-G = Colon 38; and that of 5-FU to FUMP catalysed by orotate phosphoribosyl transferase (OPRT); Colon 26 greater than or equal to Colon 38 greater than HNX-KE greater than HNX-E = HNX-DU = HNX-G. Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential sensitivity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522792      PMCID: PMC2247094          DOI: 10.1038/bjc.1989.65

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

2.  Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines.

Authors:  H R Hartmann; A Matter
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

3.  Determination of ribose 1-phosphate in ascites tumor cells.

Authors:  J Barankiewicz; J F Henderson
Journal:  Biochem Med       Date:  1977-02

4.  Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine.

Authors:  W Bollag; H R Hartmann
Journal:  Eur J Cancer       Date:  1980-04       Impact factor: 9.162

5.  Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2'-deoxyuridine as substrate.

Authors:  Y Wataya; D W Santi
Journal:  Anal Biochem       Date:  1981-03-15       Impact factor: 3.365

6.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

7.  Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine.

Authors:  H Ishitsuka; M Miwa; K Takemoto; K Fukuoka; A Itoga; H B Maruyama
Journal:  Gan       Date:  1980-02

8.  A simple and convenient assay method for phosphorolysis of 5'-deoxy-5-fluorouridine.

Authors:  M Miwa; J Nakamura; H Ishitsuka
Journal:  Gan       Date:  1981-12

9.  Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine.

Authors:  P W Woodman; A M Sarrif; C Heidelberger
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

10.  Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

Authors:  B J Braakhuis; E J Schoevers; E C Heinerman; G Sneeuwloper; G B Snow
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

View more
  6 in total

1.  Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.

Authors:  Tomomi Yamashita; Keizo Kato; Nguyen Khanh Long; Hiroki Makita; Kazuhiro Yonemoto; Kazuki Iida; Naritaka Tamaoki; Daijiro Hatakeyama; Toshiyuki Shibata
Journal:  Mol Clin Oncol       Date:  2014-03-07

Review 2.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

3.  5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.

Authors:  H Eda; Y Tanaka; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03

5.  Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.

Authors:  Hiroshi Makino; Hiroyuki Uetake; Kathleen Danenberg; Peter V Danenberg; Kenichi Sugihara
Journal:  BMC Cancer       Date:  2008-07-25       Impact factor: 4.430

6.  Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

Authors:  M de Bruin; T van Capel; K Van der Born; F A Kruyt; M Fukushima; K Hoekman; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.